NCT02273544View on ClinicalTrials.gov

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

October 31, 2002

Conditions
Healthy
Interventions
DRUG

Asasantin ER (new formulation - low)

DRUG

Asasantin ER (new formulation - medium)

DRUG

Asasantin ER (new formulation - high)

DRUG

Asasantin ER - commercial formulation

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY